Evidence map›Paper›PMID 37056852›Full record

ArticleAmerican journal of translational research2023

A miRNA-205-based model for prediction of the recurrence of endometrioid endometrial cancer.

Yaping Gan, Weifeng Feng, Liben Xu, Xinwei Guo, Yan Wang, Zhifu Chen, Lihua Zhu, Chaoyang Wu, Yingxia Ning

Abstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yaping GanDepartment of Gynaecology and Obstetrics, The First Affiliated Hospital of Jinan University Guangzhou 510632, Guangdong, China.
Weifeng FengDepartment of Traditional Chinese Medicine, The First Affiliated Hospital of Guangzhou Medical University Guangzhou 510632, Guangdong, China.
Liben XuDepartment of Radiotherapy, Jiangsu University Affiliated People's Hospital Zhenjiang 212000, Jiangsu, China.
Xinwei GuoDepartment of Radiotherapy, Yangzhou University Affiliated Taixing People's Hospital Taixing 225400, Jiangsu, China.
Yan WangDepartment of Radiotherapy, Jiangsu University Affiliated People's Hospital Zhenjiang 212000, Jiangsu, China.
Zhifu ChenDepartment of Gynaecology and Obstetrics, The First Affiliated Hospital of Jinan University Guangzhou 510632, Guangdong, China.
Lihua ZhuDepartment of Radiotherapy, Jiangsu University Affiliated People's Hospital Zhenjiang 212000, Jiangsu, China.
Chaoyang WuDepartment of Radiotherapy, Jiangsu University Affiliated People's Hospital Zhenjiang 212000, Jiangsu, China.
Yingxia NingDepartment of Gynaecology and Obstetrics, The First Affiliated Hospital of Jinan University Guangzhou 510632, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo develop a miRNA-205 based model for prediction of the recurrence of endometrial cancer.

methodsThe FIGO (International Federation of Gynecology and Obstetrics) stage, grading, myometrial infiltration, lymph node status and miRNA-205 expression levels were extracted from 90 endometrioid endometrial cancer patients, recurrence related risk factors were analyzed by Cox regression analysis. A risk model was then developed.

resultsA total of 90 endometrial cancer patients were retrospectively included for the analysis. The FIGO stage and expression levels of miRNA 205 were independently associated with the recurrence-free survival of the patients. The FIGO stage and expression levels of miRNA 205 were used for a prognostic model of recurrence-free survival. The c-index of the model reached 0.764, and the output of the model (risk score) could stratify the patients into different groups on the risk of recurrence.

conclusionA miRNA-205 based model could predict the risk of recurrence for endometrioid endometrial cancer, and the model could provide a risk stratification of patients by recurrence risk.

Indexed as

Endometrioid endometrial cancermiRNA-205recurrencerisk score

Identifiers

PMID37056852
PMCPMC10086889

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.